2017 Research Day Speaker
The keynote speaker will be Dr. John Byrd, the D. Warren Brown Chair of Leukemia Research in the College of Medicine. He will be presenting in the River Den Room in the Drake Union at 11:15am. The poster awards presentation will follow.
Directing Multiple Therapeutic Strategies toward On Targets of Ibrutinib
Ibrutinib is approved for therapeutic use in the treatment of multiple B-cell malignancies including mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, and chronic lymphocytic leukemia based upon targeting Bruton's Tyrosine Kinase (BTK). However, work by our group and others has demonstrated ibrutinib also targets kinases such as interleukin-2 inducible T-cell kinase which broadens the application of this agent to multiple diseases both in an outside of cancer therapeutics. This lecture will outline the development of Ibrutinib as the first irreversible inhibitor of BTK where unique pharmacodynamic monitoring facilitated establishing the effective dose and schedule. A discussion of unique models of disease resistance occurring with this agent and also exploitation of other on target effects such as ITK will be presented. At completion of this lecture the audience will have a general appreciation of drug development considerations for irreversible kinase inhibitors in both cancer and non-cancer related therapeutics.
This event is co-sponsored by the
Center for Clinical and Translational Science